Loading patent…
AssigneeRegulus Therapeutics Inc.
InventorsChristine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
Estimating the term…
Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
A method for inhibiting miR-122 in a cell, comprising contacting the cell with an oligomeric compound comprising an oligonucleotide consisting of 17 to 25 linked nucleosides, wherein the oligonucleotide is at least 90% complementary to nucleotides 29 to 51 of SEQ ID NO:
A method for inhibiting miR-122 in a cell comprising contacting the cell with an oligonucleotide consisting of 23 linked nucleosides and having the sequence of nucleobases set forth in SEQ ID NO:
A method for inhibiting miR-122 in a cell comprising contacting the cell with oligomeric compound comprising an oligonucleotide consisting of 15 to 30 linked nucleosides, wherein the oligonucleotide is at least 90% complementary to nucleotides 29 to 51 of SEQ ID NO:
A method for inhibiting miR-122 in a cell comprising contacting the cell with an oligonucleotide consisting of 15 to 30 linked nucleosides, wherein each nucleoside comprises a sugar modification, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage, and wherein the oligonucleotide is at least 90% complementary to nucleotides 29 to 51 of SEQ ID NO:
Dependencies are inferred from the claim text.